stop sign for vpro
Viropro Inc., a public company incorporated under the laws of the state of Nevada, specializes in the development of manufacturing processes for the production of generic biopharmaceutical drugs. The manufacturing processes developed are out-licensed to various international partners who produce and distribute the final product. Viropro's revenues come from license fees from technology transfers and royalties from the sale of final product.
Mission: To become an international leader in technology transfer for industrial production of affordable biogeneric therapeutic products to local pharmaceutical companies in emerging regions of the world with unmet medical needs such as South America, Asia, Africa and Eastern Europe.
Viropro Inc. ("Viropro") operates through Viropro International Inc., a Canadian company with its Head Office in Montreal.
Viropro International Inc. is specialized in the technology transfer, for industrial production, of affordable biological therapeutic products (also named biogeneric products, biogenerics, biopharmaceuticals or biotherapeutics) whose licenses have expired. The principal objective is to support pharmaceutical companies in South America, Asia, Africa and Eastern Europe by offering them the opportunity to locally produce and commercialize biotherapeutic products of industrial quality at an affordable price. Viropro enables emerging markets with unmet medical needs to gain access to biotherapeutics for the treatment of various diseases such as cancer, diabetes, chronic hepatitis, multiple sclerosis, and rheumatoid arthritis.
The innovative business strategy of Viropro is based on the acquisition of exclusive products and technological licenses/patents, simultaneously with the development of key partnerships with pre-eminent players on a national and international scale. Viropro has already concluded an agreement with the Biotechnological Research Institute of the National Council of Canada (Montreal: Worldwide exclusive rights to the use of patented expression systems for the production of human Interferon beta and monoclonal antibodies; scale-up and production processes).
Viropro offers the following services:
Mammalian cell line development:
Viropro offers cell line development services using various expression vector technologies (constitutive/inducible) designed for biopharmaceutical manufacturing. Industrially adapted CHO (CHO-S and DG 44) and HEK-293 cell lines can be provided for development.
Rather than investing in dhfr or un-optimized standard constitutive CMV expression vector technologies that are often pre-destined to increase development time, costs and impose a ceiling on maximal expression levels obtained, your project can certainly benefit from the technologies and know-how that Viropro has to offer your organization.
The expression vectors Viropro uses are particularly well suited for the production of MAbs as shown in the poster by Viropro and Invitrogen presented at the European Society for Animal Cell Technology (ESACT) 2009 conference in Dublin, Ireland. This serves as an example of Viropro's cell line development expertise. Our co-published data demonstrates our ability to select for an industrially interesting MAb producing cell line with yields of 2 grams/liter in a standard fed-batch process. Click here to download Viropro's standard Cell line development Fact Sheet.
Cell line stability determination:
Choosing a production clone that is sufficiently stable for scalability to manufacturing scale is crucial in process development. Through access to some of the most advanced Flow cytometry technology available, as well as standard expression stability analysis, Viropro can provide a partner with a detailed picture of expression stability of a clients cell lines. For more information of cell line stability services, please send inquiries to email@example.com or call 514 465 2722.
Mass spectrometry services for protein sequencing and characterization:
Viropro offers a diversity of Mass spectrometry services using some of the most advances instrumentation available. Proteins can often be analyzed with a resolution of 0.1 daltons. Click here to download Viropro's Mass Spectrometry services Fact Sheet.
Licensing & partnership opportunities:
Viropro is a technology company that develops cell lines and manufacturing processes. The company is not involved in product manufacturing and distribution. We are currently looking for partners interested in in-licensing our cell lines and manufacturing processes.
Viropro's business model relies on acquiring exclusive technological licenses and establishing strong partnerships with key local pharmaceutical partners through technological transfers of biogeneric therapeutic products. The local manufacturing and marketing capabilities of its partners allow Viropro to reinforce its position in these emerging markets, namely South America, Africa, Asia and Eastern Europe.
Viropro aims at providing its pharmaceutical partners access to state-of-the-art therapies with integrated turn-key solutions through comprehensive technological transfer programs going from development of industrial bioprocesses to complete training of technical teams. Our approach will allow these partners to produce therapeutic products on an industrial scale and at affordable prices, in conformity with "current good manufacturing practices" (cGMP). Through this unique business model, the company reinforces its strategic position in those emerging areas.
Further to minimising risks by sharing resources and common goals, Viropro generates revenues at each step of the technological transfer through fees and royalties, while securing a long-term stable business relationship with its partners.
1- An innovative approach in the field of biogeneric therapeutic products. Viropro provides pharmaceutical companies from emerging countries access to a new biotechnological platform allowing these companies to manufacture and bring to market biological therapeutic products at a competitive price.
2- A build-up of valuable worldwide exclusive rights.
3- The company expects to generate short to mid-term revenues from its rights, development and technology transfer expertise and long term recurring revenues from royalties on net sales made by its commercial partners related to biological therapeutic products.
4- Viropro intends to maintain a light, flexible and low overhead cost structure by out-sourcing services for non-core business activities.
5- Viropro is positioning itself in a market worth US$ 24 billion per year for the 10 biggest selling non-patented products for the treatment of diseases such as cancer, diabetes, chronic hepatitis and multiple sclerosis.
6- Viropro is entering this vital market with a solid technological platform and partnerships with local and international prominent players in product/process development.
Management Team: http://www.viropro.com/index.php?module=CMS&func=view&id=13
VPRO Media Center: http://www.viropro.com/index.php?module=SiteNews&func=view_all_news&cat=1
Investor Relations: http://www.viropro.net/index.php?module=CMS&func=view&id=41
The information contained within this iBox including web links, copied information, and any other associated messages/media (hereinafter collectively referred to as "Information") is provided for informational purposes only. The Information should not be construed as investment/trading advice and is not meant to be a solicitation or recommendation to buy, sell, or hold Viropro, Inc. (VPRO) stock.